{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:31:44Z","timestamp":1792013504018,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-022-00938-7","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T16:04:06Z","timestamp":1665417846000},"page":"1257-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood\u2013brain barrier in rodents and primates"],"prefix":"10.1038","volume":"6","author":[{"given":"Yizheng","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9440-7896","authenticated-orcid":false,"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-9773","authenticated-orcid":false,"given":"Choi-Fong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5342","authenticated-orcid":false,"given":"Fengfeng","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839\u2013862 (2019).","journal-title":"Neuron"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 641\u2013659 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.18609\/cgti.2019.141","volume":"5","author":"SJ Gray","year":"2019","unstructured":"Gray, S. J. The evolution of adeno-associated virus capsids for CNS gene therapy. Cell Gene Ther. Insights 5, 1361\u20131368 (2019).","journal-title":"Cell Gene Ther. Insights"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","volume":"7","author":"G Murlidharan","year":"2014","unstructured":"Murlidharan, G., Samulski, R. J. & Asokan, A. Biology of adeno-associated viral vectors in the central nervous system. Front. Mol. Neurosci. 7, 76 (2014).","journal-title":"Front. Mol. Neurosci."},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge, W. M. The blood\u2013brain barrier: bottleneck in brain drug development. NeuroRx 2, 3\u201314 (2005).","journal-title":"NeuroRx"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59\u201365 (2009).","journal-title":"Nat. Biotechnol."},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381\u20136388 (2004).","journal-title":"J. Virol."},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058\u20131069 (2011).","journal-title":"Mol. Ther."},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. Several rAAV vectors efficiently cross the blood\u2013brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440\u20131448 (2011).","journal-title":"Mol. Ther."},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"e0225582","DOI":"10.1371\/journal.pone.0225582","volume":"14","author":"JL Ellsworth","year":"2019","unstructured":"Ellsworth, J. L. et al. Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates. PLoS ONE 14, e0225582 (2019).","journal-title":"PLoS ONE"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/mt.2015.231","volume":"24","author":"SR Choudhury","year":"2016","unstructured":"Choudhury, S. R. et al. Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol. Ther. 24, 726\u2013735 (2016).","journal-title":"Mol. Ther."},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","volume":"15","author":"KS Hanlon","year":"2019","unstructured":"Hanlon, K. S. et al. Selection of an efficient AAV vector for robust CNS transgene expression. Mol. Ther. Methods Clin. Dev. 15, 320\u2013332 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omtm.2018.07.006","volume":"10","author":"E Hudry","year":"2018","unstructured":"Hudry, E. et al. Efficient gene transfer to the central nervous system by single-stranded Anc80L65. Mol. Ther. Methods Clin. Dev. 10, 197\u2013209 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","volume":"20","author":"M Nonnenmacher","year":"2021","unstructured":"Nonnenmacher, M. et al. Rapid evolution of blood\u2013brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol. Ther. Methods Clin. Dev. 20, 366\u2013378 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/mp300570z","volume":"10","author":"AK Deo","year":"2013","unstructured":"Deo, A. K., Theil, F. P. & Nicolas, J. M. Confounding parameters in preclinical assessment of blood\u2013brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol. Pharm. 10, 1581\u20131595 (2013).","journal-title":"Mol. Pharm."},{"key":"938_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69096-7","volume":"10","author":"HW Song","year":"2020","unstructured":"Song, H. W. et al. Transcriptomic comparison of human and mouse brain microvessels. Sci. Rep. 10, 12358 (2020).","journal-title":"Sci. Rep."},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1101\/gad.309823.117","volume":"32","author":"NM O\u2019Brown","year":"2018","unstructured":"O\u2019Brown, N. M., Pfau, S. J. & Gu, C. Bridging barriers: a comparative look at the blood\u2013brain barrier across organisms. Genes Dev. 32, 466\u2013478 (2018).","journal-title":"Genes Dev."},{"key":"938_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuron.2015.11.013","volume":"89","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37\u201353 (2016).","journal-title":"Neuron"},{"key":"938_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice. Mol. Ther. 26, 664\u2013668 (2018).","journal-title":"Mol. Ther."},{"key":"938_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux, J. et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood\u2013brain barrier. Mol. Ther. 27, 912\u2013921 (2019).","journal-title":"Mol. Ther."},{"key":"938_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182\u2013188 (2018).","journal-title":"Neurosci. Lett."},{"key":"938_CR25","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","volume":"14","author":"Q Huang","year":"2019","unstructured":"Huang, Q. et al. Delivering genes across the blood\u2013brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS ONE 14, e0225206 (2019).","journal-title":"PLoS ONE"},{"key":"938_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2019.186","volume":"31","author":"AR Batista","year":"2020","unstructured":"Batista, A. R. et al. Ly6a differential expression in blood\u2013brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum. Gene Ther. 31, 90\u2013102 (2020).","journal-title":"Hum. Gene Ther."},{"key":"938_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2021","unstructured":"Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106\u2013115 (2021).","journal-title":"Nat. Neurosci."},{"key":"938_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","volume":"16","author":"K Kardani","year":"2019","unstructured":"Kardani, K., Milani, A., S, H. S. & Bolhassani, A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin. Drug Deliv. 16, 1227\u20131258 (2019).","journal-title":"Expert Opin. Drug Deliv."},{"key":"938_CR29","doi-asserted-by":"publisher","first-page":"s267","DOI":"10.33549\/physiolres.933975","volume":"67","author":"E B\u00f6hmov\u00e1","year":"2018","unstructured":"B\u00f6hmov\u00e1, E. et al. Cell-penetrating peptides: a useful tool for the delivery of various cargoes into cells. Physiol. Res. 67, s267\u2013s279 (2018).","journal-title":"Physiol. Res."},{"key":"938_CR30","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1039\/C6CS00076B","volume":"45","author":"B Oller-Salvia","year":"2016","unstructured":"Oller-Salvia, B., S\u00e1nchez-Navarro, M., Giralt, E. & Teixid\u00f3, M. Blood\u2013brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem. Soc. Rev. 45, 4690\u20134707 (2016).","journal-title":"Chem. Soc. Rev."},{"key":"938_CR31","doi-asserted-by":"publisher","first-page":"e0139652","DOI":"10.1371\/journal.pone.0139652","volume":"10","author":"S Stalmans","year":"2015","unstructured":"Stalmans, S. et al. Cell-penetrating peptides selectively cross the blood\u2013brain barrier in vivo. PLoS ONE 10, e0139652 (2015).","journal-title":"PLoS ONE"},{"key":"938_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15623","volume":"8","author":"CF Cho","year":"2017","unstructured":"Cho, C. F. et al. Blood\u2013brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat. Commun. 8, 15623 (2017).","journal-title":"Nat. Commun."},{"key":"938_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.omtm.2021.02.019","volume":"21","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system. Mol. Ther. Methods Clin. Dev. 21, 28\u201341 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2018.05.041","volume":"176","author":"X Zhang","year":"2018","unstructured":"Zhang, X., He, T., Chai, Z., Samulski, R. J. & Li, C. Blood\u2013brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176, 71\u201383 (2018).","journal-title":"Biomaterials"},{"key":"938_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"938_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","volume":"12","author":"H B\u00fcning","year":"2019","unstructured":"B\u00fcning, H. & Srivastava, A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol. Ther. Methods Clin. Dev. 12, 248\u2013265 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","volume":"7","author":"EJ Lee","year":"2018","unstructured":"Lee, E. J., Guenther, C. M. & Suh, J. Adeno-associated virus (AAV) vectors: rational design strategies for capsid engineering. Curr. Opin. Biomed. Eng. 7, 58\u201363 (2018).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"938_CR38","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/nbt856","volume":"21","author":"OJ Muller","year":"2003","unstructured":"Muller, O. J. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040\u20131046 (2003).","journal-title":"Nat. Biotechnol."},{"key":"938_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7246","volume":"6","author":"RC M\u00fcnch","year":"2015","unstructured":"M\u00fcnch, R. C. et al. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat. Commun. 6, 6246 (2015).","journal-title":"Nat. Commun."},{"key":"938_CR40","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/12491","volume":"5","author":"A Girod","year":"1999","unstructured":"Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052\u20131056 (1999).","journal-title":"Nat. Med."},{"key":"938_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.bbrc.2004.07.054","volume":"321","author":"T Yoshida","year":"2004","unstructured":"Yoshida, T. et al. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem. Biophys. Res. Commun. 321, 961\u2013966 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"938_CR42","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.3390\/ph3123594","volume":"3","author":"JA Gomez","year":"2010","unstructured":"Gomez, J. A. et al. Cell-penetrating penta-peptides (CPP5s): measurement of cell entry and protein-transduction activity. Pharmaceuticals 3, 3594\u20133613 (2010).","journal-title":"Pharmaceuticals"},{"key":"938_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/mt.2013.266","volume":"22","author":"L Samaranch","year":"2014","unstructured":"Samaranch, L. et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol. Ther. 22, 329\u2013337 (2014).","journal-title":"Mol. Ther."},{"key":"938_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1089\/hum.2020.167","volume":"31","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux, J. et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum. Gene Ther. 31, 808\u2013818 (2020).","journal-title":"Hum. Gene Ther."},{"key":"938_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/mt.2011.3","volume":"19","author":"NM Kotchey","year":"2011","unstructured":"Kotchey, N. M. et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19, 1079\u20131089 (2011).","journal-title":"Mol. Ther."},{"key":"938_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/gt.2011.138","volume":"19","author":"G Di Pasquale","year":"2012","unstructured":"Di Pasquale, G. et al. Bovine AAV transcytosis inhibition by tannic acid results in functional expression of CFTR in vitro and altered biodistribution in vivo. Gene Ther. 19, 576\u2013581 (2012).","journal-title":"Gene Ther."},{"key":"938_CR47","doi-asserted-by":"publisher","first-page":"8179","DOI":"10.1128\/JVI.00443-13","volume":"87","author":"SM Tugizov","year":"2013","unstructured":"Tugizov, S. M., Herrera, R. & Palefsky, J. M. Epstein\u2013Barr virus transcytosis through polarized oral epithelial cells. J. Virol. 87, 8179\u20138194 (2013).","journal-title":"J. Virol."},{"key":"938_CR48","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492\u2013507 (2008).","journal-title":"N. Engl. J. Med."},{"key":"938_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"938_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria, J. N. et al. Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro. Oncol. 20, 184\u2013191 (2018).","journal-title":"Neuro. Oncol."},{"key":"938_CR51","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"938_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813\u2013824 (2007).","journal-title":"Int. Immunol."},{"key":"938_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2016","unstructured":"Nduom, E. K. et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro. Oncol. 18, 195\u2013205 (2016).","journal-title":"Neuro. Oncol."},{"key":"938_CR54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"938_CR55","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland, C. E. et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22, 1949\u20131959 (2014).","journal-title":"Mol. Ther."},{"key":"938_CR56","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1038\/onc.2011.474","volume":"31","author":"HJ Jun","year":"2012","unstructured":"Jun, H. J. et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31, 3039\u20133050 (2012).","journal-title":"Oncogene"},{"key":"938_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","volume":"99","author":"Z Karjoo","year":"2016","unstructured":"Karjoo, Z., Chen, X. & Hatefi, A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv. Drug Deliv. Rev. 99, 113\u2013128 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"938_CR58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ncb955","volume":"5","author":"M Sawada","year":"2003","unstructured":"Sawada, M., Hayes, P. & Matsuyama, S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 5, 352\u2013357 (2003).","journal-title":"Nat. Cell Biol."},{"key":"938_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mrrev.2014.06.002","volume":"763","author":"VL Fell","year":"2015","unstructured":"Fell, V. L. & Schild-Poulter, C. The Ku heterodimer: function in DNA repair and beyond. Mutat. Res. Rev. Mutat. Res. 763, 15\u201329 (2015).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"938_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13861","volume":"140","author":"SF Merkel","year":"2017","unstructured":"Merkel, S. F. et al. Trafficking of adeno-associated virus vectors across a model of the blood\u2013brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. J. Neurochem. 140, 216\u2013230 (2017).","journal-title":"J. Neurochem."},{"key":"938_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"M Simonato","year":"2013","unstructured":"Simonato, M. et al. Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9, 277\u2013291 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"938_CR62","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller, M., Giersch, L., Audrain, M., Parker, S. & Cartier, N. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27, 478\u2013496 (2016).","journal-title":"Hum. Gene Ther."},{"key":"938_CR63","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","volume":"19","author":"BC Parker Kerrigan","year":"2017","unstructured":"Parker Kerrigan, B. C., Shimizu, Y., Andreeff, M. & Lang, F. F. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy 19, 445\u2013457 (2017).","journal-title":"Cytotherapy"},{"key":"938_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrn2175","volume":"8","author":"RK Jain","year":"2007","unstructured":"Jain, R. K. et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610\u2013622 (2007).","journal-title":"Nat. Rev. Neurosci."},{"key":"938_CR65","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1038\/s41596-019-0241-8","volume":"14","author":"V Bhaskaran","year":"2019","unstructured":"Bhaskaran, V., Yao, Y., Bei, F. & Peruzzi, P. Engineering, delivery, and biological validation of artificial microRNA clusters for gene therapy applications. Nat. Protoc. 14, 3538\u20133553 (2019).","journal-title":"Nat. Protoc."},{"key":"938_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58072-w","volume":"10","author":"D Bhere","year":"2020","unstructured":"Bhere, D. et al. Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Sci. Rep. 10, 1779 (2020).","journal-title":"Sci. Rep."},{"key":"938_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon, D. A. et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4, 124\u2013135 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"938_CR68","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2019.37.15_suppl.2032","volume":"37","author":"DA Reardon","year":"2019","unstructured":"Reardon, D. A. et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). J. Clin. Oncol. 37, 2032\u20132032 (2019).","journal-title":"J. Clin. Oncol."},{"key":"938_CR69","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/neuonc\/noz226","volume":"22","author":"CI Ene","year":"2020","unstructured":"Ene, C. I. et al. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro. Oncol. 22, 639\u2013651 (2020).","journal-title":"Neuro. Oncol."},{"key":"938_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nn.4185","volume":"19","author":"D Hambardzumyan","year":"2016","unstructured":"Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20\u201327 (2016).","journal-title":"Nat. Neurosci."},{"key":"938_CR71","doi-asserted-by":"publisher","first-page":"16019","DOI":"10.1038\/mtm.2016.19","volume":"5","author":"S D\u2019Costa","year":"2016","unstructured":"D\u2019Costa, S. et al. Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol. Ther. Methods Clin. Dev. 5, 16019 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"938_CR72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/hgtb.2015.037","volume":"26","author":"A Meliani","year":"2015","unstructured":"Meliani, A. et al. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26, 45\u201353 (2015).","journal-title":"Hum. Gene Ther. Methods"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00938-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00938-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00938-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T03:13:07Z","timestamp":1668309187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-022-00938-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":72,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1038\/s41551-022-00938-7","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"13 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.B. and E.A.C. receive royalties from patents generated by this study (Patent applications: PCT\/US19\/41386, PCT\/US21\/12746 and PCT\/US22\/73051). F.B. is a co-founder and scientific advisor of Brave Bio Inc., an AAV gene therapy start-up. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}